What is "girentuximab"

Girentuximab (trade name Rencarex) is a chimeric monoclonal antibody to carbonic anhydrase IX. It is investigational agent in clinical trials for renal cell carcinoma.

Girentuximab was developed by Wilex AG.

It triggers antibody-dependent cell-mediated cytotoxicity (ADCC). It does this by activating natural killer cells by binding to carbonic anhydrase IX.